Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Raised by First Trust Advisors LP

First Trust Advisors LP increased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3,097.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 544,202 shares of the biopharmaceutical company's stock after buying an additional 527,180 shares during the period. First Trust Advisors LP owned about 0.59% of Ultragenyx Pharmaceutical worth $22,894,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Van ECK Associates Corp lifted its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock valued at $928,000 after buying an additional 294 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 493 shares during the last quarter. Arizona State Retirement System increased its position in Ultragenyx Pharmaceutical by 2.4% during the fourth quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company's stock worth $1,011,000 after buying an additional 568 shares in the last quarter. Finally, Guggenheim Capital LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 45,222 shares of the biopharmaceutical company's stock worth $1,902,000 after acquiring an additional 670 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares in the company, valued at $2,358,014.08. This represents a 5.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Emil D. Kakkis sold 25,000 shares of the company's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the completion of the sale, the chief executive officer now owns 2,158,985 shares in the company, valued at approximately $91,713,682.80. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 124,643 shares of company stock valued at $5,256,268. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 1.1 %

NASDAQ:RARE traded down $0.44 during trading hours on Thursday, hitting $38.55. The stock had a trading volume of 152,269 shares, compared to its average volume of 815,403. The business has a 50 day simple moving average of $37.54 and a two-hundred day simple moving average of $43.38. Ultragenyx Pharmaceutical Inc. has a 1-year low of $29.59 and a 1-year high of $60.37. The company has a market cap of $3.62 billion, a PE ratio of -6.09 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million for the quarter, compared to analysts' expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on RARE shares. Wedbush restated a "neutral" rating and issued a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. JPMorgan Chase & Co. raised their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Piper Sandler dropped their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. Canaccord Genuity Group increased their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $92.79.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.